IN2014DN10449A - - Google Patents

Info

Publication number
IN2014DN10449A
IN2014DN10449A IN10449DEN2014A IN2014DN10449A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A IN 10449DEN2014 A IN10449DEN2014 A IN 10449DEN2014A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A
Authority
IN
India
Prior art keywords
medicaments
medicament
substituents
salt
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Yves Auberson
Mark Gary Bock
Dario Braga
Marco Curzi
Stephanie Kay Dodd
Stefano Luca Giaffreda
Haiyang Jiang
Piotr Karpinski
Thomas J Troxler
Tielin Wang
Xiaoyang Wang
Xuechun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN10449A publication Critical patent/IN2014DN10449A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN10449DEN2014 2012-07-20 2013-07-18 IN2014DN10449A (instruction)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28
PCT/IB2013/055916 WO2014013469A1 (en) 2012-07-20 2013-07-18 Carbamate/urea derivatives

Publications (1)

Publication Number Publication Date
IN2014DN10449A true IN2014DN10449A (instruction) 2015-08-21

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10449DEN2014 IN2014DN10449A (instruction) 2012-07-20 2013-07-18

Country Status (41)

Country Link
US (4) US9034874B2 (instruction)
EP (1) EP2875016B1 (instruction)
JP (1) JP6203841B2 (instruction)
KR (1) KR102150739B1 (instruction)
CN (1) CN104470911B (instruction)
AP (1) AP3710A (instruction)
AR (1) AR092354A1 (instruction)
AU (1) AU2013291617B2 (instruction)
BR (1) BR112015001207B1 (instruction)
CA (1) CA2878006C (instruction)
CL (1) CL2015000056A1 (instruction)
CO (1) CO7170173A2 (instruction)
CR (1) CR20150019A (instruction)
CU (1) CU24248B1 (instruction)
CY (1) CY1119492T1 (instruction)
DK (1) DK2875016T3 (instruction)
EA (1) EA026091B1 (instruction)
ES (1) ES2648512T3 (instruction)
GT (1) GT201500012A (instruction)
HR (1) HRP20171692T1 (instruction)
HU (1) HUE035592T2 (instruction)
IL (1) IL236656A (instruction)
IN (1) IN2014DN10449A (instruction)
JO (1) JO3439B1 (instruction)
LT (1) LT2875016T (instruction)
MX (1) MX362059B (instruction)
MY (1) MY168752A (instruction)
NO (1) NO2875016T3 (instruction)
NZ (1) NZ702346A (instruction)
PE (1) PE20151155A1 (instruction)
PH (1) PH12014502743A1 (instruction)
PL (1) PL2875016T3 (instruction)
PT (1) PT2875016T (instruction)
RS (1) RS56479B1 (instruction)
SG (2) SG11201408020RA (instruction)
SI (1) SI2875016T1 (instruction)
TN (1) TN2014000497A1 (instruction)
TW (1) TWI597276B (instruction)
UY (1) UY34921A (instruction)
WO (1) WO2014013469A1 (instruction)
ZA (1) ZA201408805B (instruction)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN112789038A (zh) 2018-10-11 2021-05-11 诺华股份有限公司 H3r反向激动剂用于治疗与帕金森病(pd)相关的日间过度嗜睡的用途
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (instruction) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
NZ520041A (en) 2000-01-20 2004-11-26 Eisai Co Ltd Novel piperidine compounds and drugs containing the same
US6849621B2 (en) 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200503713A (en) 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2575177A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
WO2006029056A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
KR20100096222A (ko) * 2007-12-05 2010-09-01 아스트라제네카 아베 피페라진 유도체 및 렙틴 수용체 조절물질로서 그 유도체의 용도
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
SG182435A1 (en) 2010-01-22 2012-08-30 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
RS56479B1 (sr) 2018-01-31
HUE035592T2 (en) 2018-05-28
TWI597276B (zh) 2017-09-01
CO7170173A2 (es) 2015-01-28
NZ702346A (en) 2017-06-30
AU2013291617B2 (en) 2015-10-01
MX362059B (es) 2019-01-07
BR112015001207B1 (pt) 2022-08-09
JO3439B1 (ar) 2019-10-20
TW201408656A (zh) 2014-03-01
CY1119492T1 (el) 2018-03-07
HRP20171692T1 (hr) 2017-12-15
ES2648512T3 (es) 2018-01-03
IL236656A0 (en) 2015-02-26
EA026091B1 (ru) 2017-02-28
CL2015000056A1 (es) 2015-03-20
AP2014008109A0 (en) 2014-12-31
AR092354A1 (es) 2015-04-15
CU20150006A7 (es) 2016-02-29
US20160244426A1 (en) 2016-08-25
CA2878006A1 (en) 2014-01-23
SG11201408020RA (en) 2015-03-30
US9273026B2 (en) 2016-03-01
DK2875016T3 (da) 2017-11-27
CR20150019A (es) 2015-05-04
US20140163036A1 (en) 2014-06-12
PE20151155A1 (es) 2015-08-05
GT201500012A (es) 2017-11-09
EP2875016A1 (en) 2015-05-27
CA2878006C (en) 2020-10-27
PL2875016T3 (pl) 2018-01-31
AP3710A (en) 2016-05-31
US20170275264A1 (en) 2017-09-28
CN104470911A (zh) 2015-03-25
BR112015001207A2 (pt) 2017-08-01
US20150218127A1 (en) 2015-08-06
JP2015522606A (ja) 2015-08-06
WO2014013469A1 (en) 2014-01-23
EA201590250A1 (ru) 2015-05-29
EP2875016B1 (en) 2017-08-23
LT2875016T (lt) 2017-11-10
CN104470911B (zh) 2018-04-06
BR112015001207A8 (pt) 2018-01-16
PH12014502743B1 (en) 2015-02-02
ZA201408805B (en) 2016-08-31
IL236656A (en) 2017-12-31
JP6203841B2 (ja) 2017-09-27
MY168752A (en) 2018-11-30
PT2875016T (pt) 2017-11-30
US9034874B2 (en) 2015-05-19
CU24248B1 (es) 2017-02-02
UY34921A (es) 2014-02-28
SG10201700188PA (en) 2017-02-27
SI2875016T1 (sl) 2017-11-30
HK1204609A1 (en) 2015-11-27
KR20150036081A (ko) 2015-04-07
PH12014502743A1 (en) 2015-02-02
TN2014000497A1 (en) 2016-03-30
US9624192B2 (en) 2017-04-18
NO2875016T3 (instruction) 2018-01-20
AU2013291617A1 (en) 2015-01-15
KR102150739B1 (ko) 2020-09-02
MX2015000903A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
IN2015DN03998A (instruction)
PH12013500473A1 (en) Triazine-oxadiazoles
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IN2014DN10449A (instruction)
PH12015501083B1 (en) Novel pyridine derivatives
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015501843A1 (en) Novel pyrazol derivatives
IN2014DN01629A (instruction)
PH12018501709A1 (en) Naphthridinedione derivatives
IN2015DN01119A (instruction)
MY174000A (en) Novel pyridine derivatives
MX362879B (es) Usos novedosos.
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
IN2014DN10669A (instruction)
MX363458B (es) Nuevos derivados de tetrazolona.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
PH12015500373B1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
TN2013000089A1 (en) Triazine-oxadiazoles
MA37778A1 (fr) Dérivés de carbamate/urée
TN2013000327A1 (en) Novel heterocyclic derivatives